How is borderline personality disorder different from bipolar disorder?

The distinction matters because the treatments are different and misdiagnosis is common. Affective instability in BPD is typically rapid (episodes lasting hours to days) and reactive to interpersonal stressors — it arises in response to a perceived slight, rejection, or abandonment. Bipolar disorder episodes last days to weeks or months (hypomanic, manic, or depressive episodes) and often occur without a clear external trigger, though stressors can precipitate them. BPD also features the specific cluster of abandonment fears, identity disturbance, self-harm, and chronic emptiness that are not core features of bipolar disorder. The two can coexist. When in doubt, refer to psychiatry for diagnostic clarification rather than treating empirically.

What is the GP's role in managing patients with BPD?

The GP is often the most consistent, longest-term therapeutic relationship for a patient with BPD — particularly as specialist care comes and goes. Research supports that a stable, predictable, validating GP relationship is itself therapeutic: it reduces fragmentation, reduces crisis presentations, and provides relational stability that is itself healing. Practically: schedule regular planned appointments rather than waiting for crises; set clear, kind boundaries on scope and after-hours contact; resist reflex prescribing; work with (not against) the patient's mental health team; and document a crisis plan with local contacts. Project Air Strategy (NSW Health) provides GP-specific guidance sheets — the single best Australian resource.

Why should benzodiazepines be avoided in borderline personality disorder?

Benzodiazepines produce behavioural disinhibition in people with BPD — paradoxically increasing impulsivity, risk-taking, and self-harm rather than reducing them. They carry a high dependence and tolerance risk in this population, which already has elevated rates of substance use disorder. The disinhibition effect can lower the threshold for suicidal behaviour. NICE CG78 and NHMRC 2012 guidelines both explicitly recommend avoiding benzodiazepines in BPD except in specific acute crisis contexts with close clinical supervision. If anxiolytic pharmacotherapy is needed, SSRIs or SNRIs are the appropriate first-line approach; hydroxyzine or quetiapine (low-dose, short-term) may be considered as specialist-guided adjuncts.

What psychotherapies have the strongest evidence for BPD?

Dialectical behaviour therapy (DBT), developed by Marsha Linehan, has the most extensive RCT evidence — multiple trials and Cochrane reviews demonstrate reductions in self-harm, suicidal behaviour, and hospitalisation. Standard DBT involves individual therapy plus skills group (distress tolerance, emotion regulation, mindfulness, interpersonal effectiveness) over 12 months. Mentalisation-based therapy (MBT), developed by Bateman and Fonagy, has strong RCT evidence and suits outpatient or partial hospitalisation models. Schema therapy has RCT evidence showing superiority over treatment as usual for BPD and other personality disorders over 1–3 years. Good Psychiatric Management (GPM), manualised by Gunderson, is more accessible than DBT and showed comparable outcomes in a head-to-head RCT — it is more easily trained into general psychiatrists and GPs. All four are recommended by the NHMRC 2012 BPD Clinical Practice Guideline.

How should I approach self-harm in a patient with BPD?

Self-harm in BPD frequently serves a regulatory function — it reduces unbearable emotional distress, ends dissociative states, or communicates suffering. It does not automatically indicate suicidal intent, though it increases overall suicide risk. Avoid punitive or dismissive responses — 'just attention-seeking' — which are clinically inaccurate and therapeutically harmful. Assess every episode: what was the precipitant, was there suicidal intent, what is the patient's current mental state, does the injury need medical attention. Update the safety plan collaboratively. Document. Alert the mental health team. The safety planning approach (Stanley and Brown) — identifying warning signs, coping strategies, social supports, professional contacts, and means restriction — has evidence and should replace 'no-suicide contracts' which lack evidence and damage therapeutic alliance.

Personality disorders

Personality disorders: recognition and shared care in AU general practice

By Dr HB Lo, FACRRM Reviewed 15 July 2026 10 min read

Personality disorders are enduring, pervasive patterns of experience and behaviour causing significant distress, beginning in adolescence. Borderline personality disorder (BPD) — prevalence approximately 1–2% in the community — is the most common in general practice.

Treatment is psychotherapy: dialectical behaviour therapy (DBT), mentalisation-based therapy, and schema therapy have the strongest evidence. Pharmacotherapy addresses comorbidity only — no medication treats BPD. Benzodiazepines should be avoided.

The GP role is a stable therapeutic relationship, safety planning, comorbidity management, and preventing polypharmacy harm. Completed suicide rate in BPD is approximately 5–10%.

Personality disorders are among the most complex and stigmatised conditions encountered in Australian general practice. They are also far more common than many clinicians realise: borderline personality disorder (BPD) alone affects approximately 1–2% of the Australian community — meaning most GPs are regularly seeing patients with this diagnosis, whether or not it has been named. Understanding personality disorders shifts the consulting approach from managing repeated crises reactively to providing a stable, structured therapeutic relationship that is itself the evidence-based intervention.

The NHMRC 2012 Clinical Practice Guideline for the Management of Borderline Personality Disorder, the Project Air Strategy (NSW Health), and NICE CG78 provide the primary evidence-base. All three converge on the same fundamental message: treatment is psychotherapy, not medication; the GP relationship matters; and iatrogenic harm from polypharmacy is a significant risk in this population.

A. Core clinical — the AU general-practice framework

DSM-5-TR classification

The DSM-5-TR organises personality disorders into three clusters:

Cluster A — odd or eccentric:

Paranoid — pervasive distrust and suspicion of others
Schizoid — detachment from social relationships, restricted affect
Schizotypal — odd beliefs, perceptual distortions, eccentric behaviour, interpersonal deficits

Cluster B — dramatic or erratic:

Antisocial (ASPD) — disregard for and violation of others’ rights; onset of conduct disorder before age 15
Borderline (BPD) — instability in relationships, identity, and affect; impulsivity; self-harm
Histrionic — excessive emotionality and attention-seeking
Narcissistic — grandiosity, need for admiration, lack of empathy

Cluster C — anxious or fearful:

Avoidant — social inhibition, feelings of inadequacy, hypersensitivity to negative evaluation
Dependent — submissive clinging, excessive need for care, fear of separation
Obsessive-compulsive (OCPD) — preoccupation with orderliness, perfectionism, and control (distinct from OCD)

ICD-11 dimensional model: ICD-11 has replaced the categorical PD classification with a severity-based dimensional system (mild, moderate, severe) plus five trait domains (negative affectivity, detachment, dissociality, disinhibition, anankastia), with borderline pattern retained as a specifier. This approach is less stigmatising and better reflects the research evidence that personality pathology exists on a continuum with normal variation.

Borderline personality disorder — clinical focus

BPD is the most frequently encountered personality disorder in general practice and mental health settings. It is characterised by pervasive instability in relationships, self-image, and affect, combined with marked impulsivity.

DSM-5-TR criteria — five or more of nine:

Frantic efforts to avoid real or imagined abandonment
A pattern of unstable and intense interpersonal relationships alternating between idealisation and devaluation
Identity disturbance — markedly unstable self-image or sense of self
Impulsivity in two or more potentially self-damaging areas (reckless spending, substance use, unsafe sex, reckless driving, binge eating)
Recurrent suicidal behaviour, gestures, or threats; or recurrent self-harm
Affective instability due to marked reactivity of mood — intense episodic dysphoria, irritability, or anxiety usually lasting hours, rarely more than a few days
Chronic feelings of emptiness
Inappropriate intense anger or difficulty controlling anger
Transient stress-related paranoid ideation or severe dissociative symptoms

Epidemiology:

Community prevalence ~1–2% lifetime
Clinical samples show female-to-male ratio approximately 3:1, though community studies suggest a more equal sex distribution — males may be diagnosed with ASPD instead
Onset in adolescence or early adulthood; symptoms typically improve over time
McLean study longitudinal data: ~85% remission at 10 years for symptom criteria; lasting functional recovery ~50% at 10 years
Completed suicide rate approximately 5–10% — highest in comorbid depression and substance use
High comorbidity: depression, anxiety disorders, PTSD, substance use disorder, eating disorders, ADHD

Common presentations to the GP

Recurrent self-harm presentations — lacerations, burns, overdoses
Frequent crisis consultations or after-hours contacts
Multiple somatic complaints without clear organic basis
Requests for escalating doses of benzodiazepines or opioids
Conflict with healthcare providers — splitting within the team
Difficulty engaging with chronic condition management
Polypharmacy from multiple prescribers

Differential diagnosis

The most clinically important differentials to consider:

Bipolar disorder: affective episodes in bipolar last days to weeks or months and are less reactive to interpersonal triggers; refer for diagnostic clarification when in doubt
Complex PTSD (cPTSD): many BPD presentations in women are reclassified as cPTSD in ICD-11 framing; overlap with trauma history is nearly universal; trauma-informed approach is essential regardless of label
ADHD: impulsivity overlap; ADHD onset in childhood, BPD onset in adolescence; both can coexist
Major depressive disorder: chronic emptiness is core BPD; episodic depression is the comorbidity; treat comorbidity but avoid confusing it with a primary depressive disorder
Substance use disorders: very high comorbidity; must be addressed concurrently

Suicide risk and self-harm

Lifetime completed suicide rate ~5–10% — among the highest for psychiatric diagnoses
Self-harm is distinct from suicidal intent in many presentations — it often serves an emotion regulation function (rapidly reducing unbearable distress), a dissociation control function, or a communication function
Non-suicidal self-harm still elevates overall suicide risk substantially
Risk assessment at every presentation: precipitant, suicidal intent, lethality, access to means, current mental state, protective factors
Safety planning (Stanley and Brown model) has strong research support and replaces “no-suicide contracts” — safety plans identify warning signs, internal coping strategies, social supports, professional contacts, and means restriction; give the patient a written copy
Means restriction: enquire about access to medications (especially in patients who overdose), weapons; counsel family about secure storage

B. Evidence on treatment — what works, what harms

Psychotherapy — the primary treatment

NHMRC 2012, NICE CG78, and Cochrane reviews converge: psychotherapy is first-line for BPD; pharmacotherapy is adjunctive at best.

Dialectical behaviour therapy (DBT): multiple RCTs; reduces self-harm, suicidal behaviour, and hospitalisation; standard format is 12 months of individual therapy plus weekly skills group (distress tolerance, emotion regulation, mindfulness, interpersonal effectiveness); variable but growing Australian access.

Mentalisation-based therapy (MBT): Bateman and Fonagy RCTs; targets reflective capacity — the ability to understand one’s own and others’ mental states; outpatient or partial hospitalisation models; 12–18 months.

Schema therapy: RCTs showing superiority over treatment as usual for BPD and other personality disorders; targets early maladaptive schemas developed in adverse childhood experiences; 1–3 years; growing Australian access.

Good Psychiatric Management (GPM): Gunderson’s manualised approach; head-to-head RCT (McMain et al.) showed comparable outcomes to DBT; more accessible — can be trained in non-specialist settings; integrates well with GP shared care.

STEPPS (Systems Training for Emotional Predictability and Problem Solving): group-based 20-week programme; more accessible than full DBT in some settings; moderate evidence.

Pharmacotherapy — adjunctive only

No medication treats BPD directly. Prescribing targets comorbidities:

SSRIs or SNRIs — for comorbid major depression or anxiety disorder; General Schedule; do not use as primary BPD treatment
Mood stabilisers (lamotrigine, topiramate) — some evidence for impulsivity and affective instability; specialist consideration; Authority Required for bipolar indications
Low-dose antipsychotics (quetiapine 25–100 mg, olanzapine, risperidone) — some evidence for transient psychotic/dissociative symptoms, aggression; short-term only; metabolic side effects; avoid chronic use
Benzodiazepines — AVOID: disinhibition effect worsens impulsivity and self-harm; high dependence risk; no long-term efficacy; NICE CG78 explicitly recommends against; SafeScript/RTPM monitored
Review and rationalise polypharmacy at every consultation — most patients with BPD are on more medications than benefit them

Hospitalisation

Brief inpatient admission for acute suicidal crisis may be appropriate and life-saving. However, prolonged inpatient admission can entrench BPD behaviours by removing patients from their environment and the need to use adaptive coping. Brief admission plus crisis team outreach is generally preferred. Crisis assessment teams provide community alternatives. eTG complete supports this approach.

C. Australian operations

MBS items

Item 23 — Level B GP attendance
Item 36 / 44 — Level C / D consultations (frequently required for BPD review)
Item 2715 / 2717 — Mental Health Care Plan (preparation and review)
Item 80000–80020 — psychology Better Access (10 subsidised sessions/year; up to 10 additional with psychiatrist letter)
Item 81335 — telehealth psychology
Item 291 / 293 — psychiatrist consultation
Item 132 / 133 — consultant physician (psychiatry) initial and subsequent
Item 965 / 967 — GPCCMP (replacing GPMP/TCA from 1 July 2025); supports chronic complex mental health care coordination
Item 715 / 707 — ATSI Health Assessment / 75+ Health Assessment — include mental health review

MBS items: mbsonline.gov.au.

PBS prescribing

SSRIs, SNRIs — General Schedule
Mood stabilisers (lamotrigine, valproate, lithium, topiramate) — Authority Required for bipolar, treatment-resistant depression, or specialist indications
Antipsychotics (quetiapine, olanzapine, risperidone, aripiprazole) — Authority Required for psychotic disorders, bipolar mania; off-label for BPD
Benzodiazepines — General Schedule; SafeScript/RTPM monitored; avoid in BPD
Naltrexone — Authority for opioid or alcohol use disorder comorbidity

PBS details: pbs.gov.au.

Key Australian resources

Project Air Strategy (NSW Health / University of Wollongong) — clinician fact sheets, GP guides, family resources, crisis planning templates; the single best Australian resource for GPs managing BPD
Spectrum BPD Service Victoria — specialist tertiary consultation-liaison service; provides consultation to treating teams
MindSpot — free iCBT; no GP referral required; useful adjunct for anxiety/depression comorbidity
Sane Australia — peer support, lived experience community, resources for complex mental illness
Lifeline 13 11 14 — crisis line
Suicide Call Back Service 1300 659 467

Shared care model — the GP role

The most effective structure is one stable GP plus one treating psychotherapist or psychiatrist, with clear communication lines and a documented crisis plan:

Predictable, structured appointments — regular scheduled visits (not crisis-only)
Clear, kind boundaries — scope of GP role; after-hours pathway; prescribing role (one prescriber)
Safety plan — written; updated at every change in risk; copies held by patient and documented in record
Crisis pathway — state mental health crisis line (Vic: 1300 369 012; NSW: 1800 011 511; Qld: 1300 642 255; WA: 1800 676 822; SA: 13 14 65)
Family and carer support — Project Air family fact sheets; psychoeducation
Monitor for iatrogenic harm — polypharmacy, benzodiazepines, opioids; SafeScript review

Crisis pathways by state

Victoria: mental health crisis line 1300 369 012
New South Wales: mental health crisis line 1800 011 511
Queensland: 1300 642 255
Western Australia: 1800 676 822
South Australia: 13 14 65
National: Lifeline 13 11 14; Suicide Call Back Service 1300 659 467

D. Australian operations — additional

Workers’ compensation and Centrelink contexts: Disability Support Pension may be relevant for severe persistent personality disorder with significant functional impairment. NDIS eligibility for psychosocial disability is possible for moderate-to-severe PD with functional impact — application support from the treating team helps. Document functional capacity objectively; avoid diagnostic labels in documentation that is not clinical if this would create barriers to support access.

E. Special populations

Adolescents. Personality disorder features are often detectable in adolescence but full diagnosis is generally deferred until adulthood because traits are less stable and normal adolescent development overlaps with some features. Youth mental health services (headspace, EPPIC) provide age-appropriate pathways. DBT has evidence for adolescents with self-harm.

Older adults. BPD features often improve with age — this is a message of hope. Late-life presentations may reflect undiagnosed BPD that has been managed as depression or anxiety for decades. Polypharmacy risk is particularly high in older adults with long-standing personality disorder.

Aboriginal and Torres Strait Islander patients. Intergenerational trauma, racism within healthcare systems, and social determinants of health are central to understanding distress presentations. Cultural safety and trauma-informed care are prerequisite to effective engagement. Working with ACCHO services and Aboriginal Liaison Officers where available supports care.

Patients with comorbid substance use. Address substance use concurrently — it is both a comorbidity and a driver of BPD presentation severity. Naltrexone for opioid or alcohol use disorder has evidence; harm reduction frameworks suit this population.

When to escalate

Emergency services (000 / ED) when: acute suicidal crisis with intent and plan, serious self-injury requiring medical attention, imminent risk to self or others.

State mental health crisis assessment team: acute suicidal crisis with high risk but not requiring immediate ED.

Routine psychiatric referral: diagnostic uncertainty (BPD vs bipolar vs complex PTSD), treatment-resistant presentations, complex comorbidity, biologic pharmacotherapy consideration.

Psychology via MHCP: first-line; specify DBT or MBT experience if possible in the referral.

What this article is and is not

This article is general health information based on the NHMRC 2012 BPD guideline, Project Air Strategy, NICE CG78, RANZCP guidelines, eTG complete, and Cochrane systematic reviews. It is not personal medical advice and does not create a doctor–patient relationship. Individual treatment decisions are made with your treating clinicians.

For Australian consumer and peer support resources: Sane Australia, Project Air, MindSpot.

For crisis support: Lifeline 13 11 14, Suicide Call Back Service 1300 659 467, Beyond Blue 1300 22 4636, 13YARN 13 92 76 (First Nations).

Sources cited

Frequently asked questions

How is borderline personality disorder different from bipolar disorder?

The distinction matters because the treatments are different and misdiagnosis is common. Affective instability in BPD is typically rapid (episodes lasting hours to days) and reactive to interpersonal stressors — it arises in response to a perceived slight, rejection, or abandonment. Bipolar disorder episodes last days to weeks or months (hypomanic, manic, or depressive episodes) and often occur without a clear external trigger, though stressors can precipitate them. BPD also features the specific cluster of abandonment fears, identity disturbance, self-harm, and chronic emptiness that are not core features of bipolar disorder. The two can coexist. When in doubt, refer to psychiatry for diagnostic clarification rather than treating empirically.
What is the GP's role in managing patients with BPD?

The GP is often the most consistent, longest-term therapeutic relationship for a patient with BPD — particularly as specialist care comes and goes. Research supports that a stable, predictable, validating GP relationship is itself therapeutic: it reduces fragmentation, reduces crisis presentations, and provides relational stability that is itself healing. Practically: schedule regular planned appointments rather than waiting for crises; set clear, kind boundaries on scope and after-hours contact; resist reflex prescribing; work with (not against) the patient's mental health team; and document a crisis plan with local contacts. Project Air Strategy (NSW Health) provides GP-specific guidance sheets — the single best Australian resource.
Why should benzodiazepines be avoided in borderline personality disorder?

Benzodiazepines produce behavioural disinhibition in people with BPD — paradoxically increasing impulsivity, risk-taking, and self-harm rather than reducing them. They carry a high dependence and tolerance risk in this population, which already has elevated rates of substance use disorder. The disinhibition effect can lower the threshold for suicidal behaviour. NICE CG78 and NHMRC 2012 guidelines both explicitly recommend avoiding benzodiazepines in BPD except in specific acute crisis contexts with close clinical supervision. If anxiolytic pharmacotherapy is needed, SSRIs or SNRIs are the appropriate first-line approach; hydroxyzine or quetiapine (low-dose, short-term) may be considered as specialist-guided adjuncts.
What psychotherapies have the strongest evidence for BPD?

Dialectical behaviour therapy (DBT), developed by Marsha Linehan, has the most extensive RCT evidence — multiple trials and Cochrane reviews demonstrate reductions in self-harm, suicidal behaviour, and hospitalisation. Standard DBT involves individual therapy plus skills group (distress tolerance, emotion regulation, mindfulness, interpersonal effectiveness) over 12 months. Mentalisation-based therapy (MBT), developed by Bateman and Fonagy, has strong RCT evidence and suits outpatient or partial hospitalisation models. Schema therapy has RCT evidence showing superiority over treatment as usual for BPD and other personality disorders over 1–3 years. Good Psychiatric Management (GPM), manualised by Gunderson, is more accessible than DBT and showed comparable outcomes in a head-to-head RCT — it is more easily trained into general psychiatrists and GPs. All four are recommended by the NHMRC 2012 BPD Clinical Practice Guideline.
How should I approach self-harm in a patient with BPD?

Self-harm in BPD frequently serves a regulatory function — it reduces unbearable emotional distress, ends dissociative states, or communicates suffering. It does not automatically indicate suicidal intent, though it increases overall suicide risk. Avoid punitive or dismissive responses — 'just attention-seeking' — which are clinically inaccurate and therapeutically harmful. Assess every episode: what was the precipitant, was there suicidal intent, what is the patient's current mental state, does the injury need medical attention. Update the safety plan collaboratively. Document. Alert the mental health team. The safety planning approach (Stanley and Brown) — identifying warning signs, coping strategies, social supports, professional contacts, and means restriction — has evidence and should replace 'no-suicide contracts' which lack evidence and damage therapeutic alliance.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.